dopexamine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Dopexamine is a synthetic analogue of dopamine that is administered intravenously in hospitals to reduce exacerbations of heart failure and to treat heart failure following cardiac surgery. It is not used often, as more established drugs like epinephrine, dopamine, dobutamine, norepinephrine, and levosimendan work as well. It works by stimulating beta-2 adrenergic receptors and peripheral dopamine receptor D1 and dopamine receptor D2. It also inhibits the neuronal re-uptake of norepinephrine.   Wikipedia

Chemistry

  • SMILES: Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O
  • InChIKey: RYBJORHCUPVNMB-UHFFFAOYSA-N
  • Mol. Mass: 356.51
  • ALogP: 3.62
  • ChEMBL Molecules:
    None  
    dopexamine  
More Chemistry

Pharmacology

Alternative names

dopacard | dopexamine | dopexamine dihydrobromide | dopexamine dihydrochloride | dopexamine hcl | dopexamine hydrochloride | fpl 60278 | fpl-60278 | fpl-60278ar

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Heart Failure

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Free Tissue Flaps (Phase 4)

Head and Neck Neoplasms (Phase 4)

Heart Failure ()

Hypotension (Phase 4)

Mouth Neoplasms (Phase 4)

Shock, Septic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue